Tags : Amathus Therapeutics


Merck Collaborates with Amathus Therapeutics to Develop Treatments for Neurodegenerative

Shots: Amathus to receive upfront and will be eligible for ~$500M milestones/program, if Merck exercise its option and will be responsible for identifying & progressing novel chaperone activators through preclinical discovery Merck to get an option to acquire Amathus Therapeutics along with its pipeline of mitochondrial targeted candidate to treat neurodegenerative disorders and renal diseases […]Read More